{"id":"NCT03748953","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)","officialTitle":"China Continuation: A Single-Arm, Open-Label Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-24","primaryCompletion":"2023-12-06","completion":"2023-12-06","firstPosted":"2018-11-21","resultsPosted":"2025-03-21","lastUpdate":"2025-03-21"},"enrollment":37,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Ixazomib","otherNames":[]}],"arms":[{"label":"Ixazomib","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.","primaryOutcome":{"measure":"Number of Participants Categorized According to Performance Status (PS) Based on Eastern Cooperative Oncology Group (ECOG) PS","timeFrame":"Month 25","effectByArm":[{"arm":"Ixazomib","deltaMin":34,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b603a4db2bf003ab4a2b7?idFilter=%5B%22C16021CSC%22%5D"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":35},"commonTop":["Upper respiratory tract infection","Diarrhoea","Vomiting","COVID-19","Platelet count decreased"]}}